{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-211843","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.914425+00:00","generated_at":"2026-06-24T04:21:37.341446+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AlloVir Q2 net loss $44.6M; $126.5M July offering extends cash runway for Phase 3 trials","bullets":["Net loss $44.6M ($0.69/sh) vs $37.6M ($0.60/sh) in Q2 2021; R&D expense rose to $31.4M.","Cash $172.7M at June 30; July registered direct offering raised $126.5M to fund three Phase 3 posoleucel trials.","Phase 2 multi-virus prevention final data expected year-end; Phase 2 BKV treatment topline in Q1 2023.","Posoleucel granted EMA orphan designation for prevention; now holds three FDA RMAT designations.","FY2022 operating expense guidance $130-145M, excluding stock-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-211843","json":"https://secwatch.observer/filing/0001193125-22-211843.json","markdown":"https://secwatch.observer/filing/0001193125-22-211843.md","text":"https://secwatch.observer/filing/0001193125-22-211843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522211843/0001193125-22-211843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522211843/d308599d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:21:37.341446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}